Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Check out the approved cancer indications for Ketruda. Why can't we get the same for neurological indications for our Blacamesine?
https://www.keytruda.com/how-d/
Scroll down to FDA-Approved Indications.
When that’s all the negative stuff fudsters can come up with, we’re in good shape. Let them think they have that. Pitiful.
Lie with dogs, get fleas. That is the perception of companies that engage with LPC.
Missling does not want to have to put up with serious biotech investors who are going to ask hard questions, demand straight answers, and put his feet to the fire and hold him accountable when he screws up. He’s perfectly happy to have index funds own his stock as well as retail investors who worship at his feet and defend his every utterance without applying any critical thinking.
By all means, trading to make a few bucks on the volatility is perfectly reasonable, but let’s not pretend Missling is going to upend medicine.
If the Anavex story had any validity, then Missling, together with a top investment bank or banks, would be able to put together an “A” list of biotech institutional investors to finance the company long term and give it credibility where today it has precious little. All Anavex would need is a few bellwether investor names (firms like Perception Life Sciences, Janus Life Sciences Fund, and Biotechnology Value Fund) and we’d truly be on our way. The Street’s perception of Anavex would do a 180, from third-tier curiosity to serious player. Likewise, healthcare/business reporters at major news organizations would suddenly take an interest and bring the Anavex story to a much wider audience. Ditto for potential partners.
Would that red herring by any chance be with chocolate sauce?
Looking forward to hearing more from you regarding Set Theory.
May The Flying Spaghetti Monster be with you,
Lincoln Park Capital is a red herring non-issue for AVXL.
https://www.lpcfunds.com/about/
GOD bless,
Hmmmm. Can't be all that bad. In 2018 AVXL stock was in the $3 range, now it is in the $10-$11 range. I guess AVXL is not in the majority of Lincoln Park victims.
Next time see if you can come up with something relevant to AVXL and how it funds its progress.
I agree with everything you said in your post. The worst possible message Missling could send to serious biotech investors is to get back in bed with a vulture investor like LPC. It’s no wonder not a single biotech institutional investor owns this stock and why several of the analysts covering the stock seem to be stepping back. But this is how Missling apparently wants it. With LPC in place, he can avoid scrutiny from knowledgeable, unemotional biotech investors and avoid accountability for missed milestones and other screw ups.
It’s just amazing how powerful an emotion hope is for retail investors and how it can warp one’s perception of reality. After so many years, the MO is both obvious and predictable. Wash, rinse, and repeat year after year after year. It would be funny if it weren’t so sad and so costly, not only to shareholders but to patients.
Remember this: FUD means Facts, Understanding and Data.
Whit your great understanding if the NDA process what do you think Missling could do to speed things up?
Please include scheduling process of FDA meetings, FDA review times, data analysis , lab analysis, clinical trial report process preparation.
Like I said, the market does NOT like this deal with Lincoln Capital. Aren't you tired of losing 7-10% of the value of this stock on any given day? I know I am.
Anavex's blarcamesine and/or Anavex 3-71 can treat and/or prevent ALS (Lou Gehrig's disease)
Sigma-1 receptor maintains ATAD3A as a monomer to inhibit mitochondrial fragmentation at the mitochondria-associated membrane in amyotrophic lateral sclerosis
I would welcome approval by any agency any time without the need for any bragging rights.
Anavex's blarcamesine and/or Anavex 3-71 can be used to treat and/or prevent cardiovascular diseases including pulmonary arterial hypertension (PAH) and atrial fibrillation (AF).
*******************************************************
Missling is a horrible CEO
- Vulture financing - giving finger to WS
- Did financing cause he knows they're won't be revenue for a very long time. WS knows it too and won't touch the dumpster fire.
- Tries to hide the vulture financing - burying it in the Q (last page) - just shady has hell
- Misses every self imposed milestone - his answer on the call Tuesday was a joke = "easy to start trials, hard to finish" So what, your job as the leader of the company is make it happen. Missling just waved his hands in the air and said don't blame me.
- His solution is not to provide any milestone guidance - giving finger to WS
- Every data release is effed up in some way
- I think longs need to entertain the idea that Missling is a grifter and longs are suckers
- I think for planning purposes longs should assume nothing meaningful happens this year with the exception of announcing the need for a Phase 3 trial in AD - putting commercialization in 2028
- Rett data in 2nd half of 2023 means Feb'ish 2024
- I will be getting short asap
Tell you what, if the FDA gives an approval on this AD trial, your remaining five percent chance will not bestow bragging rights.
Why only Until Rett EXCELLENCE?
To me it is now looking more like the 95% chance of PM P3 like Doc settled on at the time of my generous 75%.
I bet they diluted that 158k today that cleared after hours. Nothing like getting right to it and punishing investors.
baby seal day for AVXL
The stock is a boon for those who are willing to trade(since CTAD in December).
Until Rett EXCELLENCE
So now is juts in case we run a PM P3 ¿
Just in case doesn't sound like 75% to me.
Different interpretation of the exercise price in the terms of the agreement.
The "Net" to Anavex varies.
I honestly do not even know where to start.
I scanned your post of the terms.
Deleted?
My interpretation....always subject to debate.
Hey Leo! Somehow I got a glimpse of your response to one of my posts with regards to something about $10 and a floor right before you updated and deleted it LOL
Here's to hoping that your "P3 PM trials before approval" prediction turns out to be nowhere nearly as accurate as your "AVATAR results in Feb'ish 2022" turned out to be!
More likely just after 10:16 AM today.
Those funds will be very good to have just in case Anavex needs to run a bunch P3 Precision Medicine trials before any approvals are likely.
LPC sold their 75000 sign in shares yesterday. Today is dump day meaning LPC calling Misleading to release daily quota, expect tomorrow or Friday another run up, LPC need to sell hose share to blind followers.
Certain of what, Set Theory?
Correct ignatiusrielly35.
75,000 shares were awarded yesterday; another 75,000 additional shares will be awarded in the future.
Basically it amounts to a 1% commission if the full $150M is raised @ $10 per share average (or only 0.5% commission if raised @ $20 per share avg...or only 0.25% commission if raised @ $40 per share avg...)
Anavex is a small company competing with companies with deep pockets and lots of influence. TGD will get together all the documentation needed to increase the Odds of acceptance. We have come a long way. Know what you own.
Especially those who bought from 12 to 31.50.
Actually I am more certain than ever.
I am absolutely certain that Roche is interested in partnering with or buying Anavex Life Sciences or licensing Blarcamesine from Anavex.
I have heard and believe that JNJ and Pfizer among other big Pharma are also interested in Anavex Life Sciences.
Good luck and GOD bless,
Not correct. The share price for any shares that may be placed is the current market price, determined in various ways. There is no floor price limit.
You misplaced a decimal. It’s 75,000 shares.
I am absolutely certain that Roche is interested in partnering with or buying Anavex Life Sciences or licensing Blarcamesine from Anavex.
I have heard and believe that JNJ and Pfizer among other big Pharma are also interested in Anavex Life Sciences.
Good luck and GOD bless,
There really are some delusional posts here. How on Earth do you get to those conclusions from all the absolutely useless news yesterday?
Max of $15 by 2026. Go figure.
Wow, Do you even know if Anavex applied for an approval of the new AD drug in Australia, European Union and UK?
That would go first; I didn’t hear the news.
WRONG. The terms are different.
IF you need money...today it costs more than it did even recently.
Does the WGT crowd insist Anavex does not need money?
IMHO...today MOC down 5%+ on this GREAT NEWS.
Hey George....
Above or below even for the day on the GREAT News about LPC?
You are addressing total BS from MIKE! The real facts that will quickly drive revenues for ANAVEX are:
1. Approval for A 2-73 for ALZHEIMERS in AUSTRALIA.
2. Approval for A 2-73 for ALZHEIMERS in EUROPEAN UNION, and UNITED KINGDOM ( BRITAIN & CANADA ). This can and probably will occur in MAY 2023.
3. Approval for A 2-73 for RETT SYNDROME in the UNITED STATES in JULY 2023, two months after EXCELLENCE TRIAL reports TLR! Also, award of $100M voucher from FDA.
4. Approval for A 2-73 for A 2/73 for ALZHEIMERS in the UNITED STATES in August 2023!
Net result ANAVEX ROCKETS TO $100+ in June 2023!
Cantor brought to the table more stable entities.
LPC will NEVER hold the shares Anavex decides to exercise.
I raised my skunk from low 9s, but think now that may be appropriate.
So $10 is the floor and everything above is of benefit to LPC?
Did I get that right?
So penal IF the WGT are correct and the SP goes nowhere but UP?
No. I only briefly scanned the terms but it appears LPC is receiving 750,000 shares now and another potential 750,000 shares depending on how many shares its required to purchase. Consider it a cheap insurance premium to secure up to $150mm in emergency funding.
LPC is going to make money in other ways too, but this seems to be a fair deal all around and comparable to the Cantor deal.
This Lincoln Park ATM option is used as as red herring for the FUDsters.
GOD bless,
Followers
|
1085
|
Posters
|
|
Posts (Today)
|
84
|
Posts (Total)
|
471224
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |